Good MorningThe equities market made an abrupt about-face on Thursday as fear that a deadlock in Washington will put an end to the market melt-up. A lingering impasse has held up talks between Congressional Democrats and White House Republicans keeping aid from millions of needy Americans. The tech-heavy NASDAQ Composite led the day’s rout with a loss of 5.0% with much of the weakness in FAANG names.
The S&P 500 and Dow Jones Industrial Average both shed smaller if no less alarming, amounts. In technical terms, Thursday’s price action confirms near-term reversals that could lead the indices much lower. For now, traders will be closely watching the 30-day moving average for signs of weakness. If price action on the indices falls below that level a much deeper correction could be in store.
Featured: President Trump’s Project MAFA (Ad) 
|
Markets | | |
This year, the era of cloud technology dominance has officially begun. With cloud stocks leading the Nasdaq to record highs regularly, many investors are trying to figure out just how much potential these companies will have over the next decade. It’s easy to understand why businesses that a... Read the Full Story |
|
From Our Partners | | A little-known Title 15 provision could let you collect instant payouts — $100 to $1,000 — directly from your smartphone.
You don’t need to trade stocks or own assets. Jeff Clark has used this strategy for years with elite clients, and now he’s revealing it in a short video for everyday Americans. | | Watch how to collect your first payout here |
|
Markets | | | Intuitive Surgical (NASDAQ:ISRG) is a company producing cutting-edge medical technology that is changing the way that surgeries are performed. Here are some reasons why this stock could be a great buy Read the Full Story |
|
Markets | | | Fast casual restaurant chain Red Robin Gourmet Burgers (NASDAQ: RRGB) stock has been dormant during the pandemic recovery even as the benchmark S&P 500 index (NYSEARCA: SPY) make new all-time highs. However, shares have finally awoken as money looks for laggard opportunities among the rapidly ac... Read the Full Story |
|
From Our Partners | Will you be Larry's next breakout protégé?
For the past three years, Larry Benedict's "protégés" have had the chance to beat the market by 8x.
But it hasn't happened the usual way.
It's all thanks to something he calls the "Market Wizard Protégé Program."
For every dollar others make, you could make 2x, 5x, even 10x more — using the same stocks.
It almost sounds like magic, but it's true.
Is this radical program suitable for you? | | Click here to see for yourself — including the #1 stock Larry recommends trading today. |
|
Tech | | | Salesforce.com Is Only The Tip Of The Iceberg
Salesforce.com (NYSE:CRM) shocked the market when it reported earnings for the 2nd quarter. We knew the pandemic had accelerated the shift to digital and with it the cloud but the numbers are mind-boggling. Salesforce.com, a company whose business is he... Read the Full Story |
|
Markets | | |
Ambarella, A Diversified Play On Specialty Semiconductors
Ambarella (NASDAQ:AMBA) made a name for itself providing chips and technology for GoPro’s (NASDAQ:GPRO) popular line of digital, connected, cameras. Unfortunately for both companies, the GoPro narrative did not play out quite as we t... Read the Full Story |
|
From Our Partners | | Congress is deep into “Crypto Week” — with new bills that could finally bring clarity to digital assets.
Crypto analyst Juan Villaverde says Bitcoin will likely keep climbing… but smaller coins could deliver far bigger gains. He’s revealing the altcoins he believes are best positioned for this new regulatory era. | | See Juan’s top altcoin picks for the new crypto bull cycle |
|
The Early Bird Stock Of The Day Sorrento Therapeutics, Inc., a clinical and commercial stage biopharmaceutical company, develops a portfolio of next-generation treatments for three therapeutic areas: cancer, infectious disease,and pain. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutic by leveraging its proprietary G-MAB antibody library and targeted delivery modalities, which include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy, and antibody drug conjugate, as well as bispecific antibody approach; and Sofusa, a drug delivery technology that deliver biologic directly into the lymphatic system. Its clinical programs in development include anti-CD38 CAR-T therapy for the treatment of multiple myeloma, as well as for amyloidosis and graft versus host disease. The company develops resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin for late stage cancer and osteoarthritis pain treatment; and ZTlido, a lidocaine topical system for the treatment of post-herpetic neuralgia. It engages in the development of SEMDEXA, an injectable viscous gel formulation, which is Phase III trial for the treatment of sciatica, a pathology of low back pain; SP-103, an investigational non-aqueous lidocaine topical system undergoing clinical development in chronic low back pain condition; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation for the treatment of fibromyalgia. It has collaboration with SmartPharm Therapeutics Inc. to develop gene-encoded antibody vaccine to protect against COVID-19; and Mayo Clinic for Phase Ib pilot study using sofusa lymphatic drug delivery technology to deliver Ipilimumab in patient with melanoma. The company was founded in 2006 and is based in San Diego, California. On February 13, 2023, Sorrento Therapeutics, Inc., along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of Texas. The plan was later approved as Chapter 11 liquidation on November 30, 2023. | | View Today's Stock Pick |
|
